Kyntra Bio sought Nasdaq review and Kyntra Bio stock costs EUR 5.45

Published on 10/08/2026 at 10:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq requires USD 50.00 million in assets and revenue. Kyntra Bio stock costs EUR 5.45 on October 8, 2026 after EUR 5.53.

KYNB, US31572Q8814, Illustration mit AI erstellt.

Kyntra Bio (ISIN US31572Q8814) sought Nasdaq review of a delisting determination dated September 30, 2026, while Kyntra Bio stock was at EUR 5.45 at Lang & Schwarz on October 8, 2026. The company remains listed while the Nasdaq panel considers its request, according to StockTitan.

Nasdaq review keeps trading open

The September 30, 2026 filing said Nasdaq staff had determined to delist the common stock after the company failed to demonstrate compliance by September 29, 2026. Kyntra Bio requested a hearing before the Nasdaq Hearings Panel, which keeps the suspension of its securities and a Form 25-NSE filing on hold while the review proceeds.

The potential extension could last up to 180 days from the staff determination, according to StockTitan. The filing also said the company was preparing a compliance plan, making the panel decision a direct trading and financing issue rather than a routine corporate update.

The listing test sets a high bar

Nasdaq's cited standard requires at least USD 50.00 million in total assets and USD 50.00 million in total revenue for the most recently completed fiscal year or two of the three most recent fiscal years. The filing also referenced alternative stockholders' equity and market-value requirements that Kyntra Bio had not satisfied.

That threshold matters against Kyntra Bio's USD 24.8 million market capitalization as of October 7, 2026. The comparison shows why the listing review carries more weight than the board change reported by GlobeNewswire on October 1, 2026. Andrew E. Singer joined the board and its Audit Committee, while Maykin Ho stepped down on September 30, 2026.

Stock stays below its prior close

Kyntra Bio stock was trading at EUR 5.45 at Lang & Schwarz on October 8, 2026 at 10:39 a.m. CEST, down 1.45 percent versus the prior close of EUR 5.53. The move leaves the listing decision as the central near-term company-specific issue for the security, while the Nasdaq panel reviews the hearing request.

The further course of trading is shown by the continuously updated real-time quote of Kyntra Bio stock.